The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1011
October 10, 1997
View Complete Issue         Table of Contents 2019 
Tamsulosin for Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tamsulosin for Benign Prostatic Hyperplasia
October 10, 1997 (Issue: 1011)
Tamsulosin (Flomax - Boehringer Ingelheim), an alpha 1 - adrenoreceptor blocker, has been approved by the FDA for treatment of benign prostatic hyperplasia (BPH). It is claimed to bind preferentially to alpha1 receptors in the prostate.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tamsulosin for Benign Prostatic Hyperplasia
Article code: 1011c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.